MannKind Corporation (MNKD)
| Market Cap | 1.21B -4.0% |
| Revenue (ttm) | 360.78M +21.2% |
| Net Income | -23.91M |
| EPS | -0.09 |
| Shares Out | 308.95M |
| PE Ratio | n/a |
| Forward PE | 544.44 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,662,681 |
| Open | 3.890 |
| Previous Close | 3.870 |
| Day's Range | 3.880 - 4.020 |
| 52-Week Range | 2.230 - 6.510 |
| Beta | 1.11 |
| Analysts | Strong Buy |
| Price Target | 7.59 (+93.62%) |
| Earnings Date | Aug 5, 2026 |
About MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in... [Read more]
Financial Performance
In 2025, MannKind's revenue was $348.97 million, an increase of 22.23% compared to the previous year's $285.50 million. Earnings were $5.86 million, a decrease of -78.75%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for MNKD stock is "Strong Buy." The 12-month stock price target is $7.59, which is an increase of 93.62% from the latest price.
News
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use
MannKind Transcript: Jefferies Global Healthcare Conference 2026
Recent pediatric approval for Afrezza is expected to drive significant growth, with early launch signals showing strong demand and a compounding effect as children transition to adult care. FUROSCIX is on track for auto-injector approval, supporting robust revenue guidance, while the pipeline advances with inhaled nintedanib and other programs.
MannKind announces milestones in development of nintedanib DPI for IPF
MannKind (MNKD) announced key clinical execution milestones in the development of nintedanib DPI for idiopathic pulmonary fibrosis, or IPF, including the completion of patient randomization in the U.S...
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2
MannKind price target raised to $11 from $10 at Wells Fargo
Wells Fargo raised the firm’s price target on MannKind (MNKD) to $11 from $10 and keeps an Overweight rating on the shares. The firm cites Afrezza’s approval in pediatric patients…
MannKind Transcript: FDA announcement
Afrezza received FDA approval for pediatric use in patients six and older, offering the first inhaled mealtime insulin alternative to injections. Clinical trials showed non-inferior efficacy, stable lung function, and improved satisfaction. Launch efforts focus on education, access, and rapid adoption.
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA ...
US FDA approves MannKind's inhaled insulin for children
The U.S. Food and Drug Administration has approved expanded use of MannKind's inhaled rapid-acting insulin in children with diabetes, offering patients under 18 years of age a needle-free treatment...
MannKind announces FDA approval of Afrezza for use in children aged 6 and older
MannKind (MNKD) announced that the U.S. Food and Drug Administration has approved Afrezza Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and…
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
MannKind Announces FDA Approval of Afrezza® the 1st & Only Inhaled Mealtime Insulin for Use in Children & Adolescents Aged 6 and Older Living with Diabetes
MannKind to Present at Jefferies Global Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that Chief Executive Officer, Michael Castagna, PharmD will participa...
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
MANNKIND TO SHOWCASE NEW DATA AT ADA 2026 ADVANCING UNDERSTANDING OF INHALED INSULIN (AFREZZA®) IN PEDIATRIC CARE, PREGNANCY AND USE WITH AID SYSTEMS
MannKind Transcript: AGM 2026
The meeting confirmed a quorum, elected nine directors, and approved executive compensation and auditor ratification. Strategic updates included major product launches, pipeline progress, and revenue growth projections, with Q&A addressing diversification and partnership strategies.
MannKind price target lowered to $7 from $8 at Mizuho
Mizuho analyst Anthony Petrone lowered the firm’s price target on MannKind (MNKD) to $7 from $8 and keeps an Outperform rating on the shares.
MannKind price target raised to $10 from $8 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on MannKind (MNKD) to $10 from $8 and keeps a Buy rating on the shares. MannKind’s Q1 results missed estimates but this does…
MannKind price target raised to $10 from $8 at Wells Fargo
Wells Fargo raised the firm’s price target on MannKind (MNKD) to $10 from $8 and keeps an Overweight rating on the shares following the disclosure of the company’s involvement with…
MannKind reports Q1 EPS (2c), consensus 1c
Reports Q1 revenue $90.17M, consensus $105.31M. “We are making meaningful progress executing our corporate transformation strategy, focused on the expansion and diversification of both our commercial ...
MannKind Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 15% year-over-year to $90M, driven by FUROSCIX and strong underlying demand. Two major regulatory catalysts—Afrezza Pediatrics and FUROSCIX ReadyFlow—are expected to accelerate growth in the second half, with reaffirmed 2026 FUROSCIX revenue guidance of $110M-$120M.
MannKind Earnings release: Q1 2026
MannKind released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
MannKind Quarterly report: Q1 2026
MannKind has published its Q1 2026 quarterly earnings report on May 6, 2026.
MannKind Slides: Q1 2026
MannKind has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a biopharmaceutical company dedicated to transforming chronic disease care through inn...
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of rali...
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through ...
MannKind price target lowered to $8 from $10 at Mizuho
Mizuho lowered the firm’s price target on MannKind (MNKD) to $8 from $10 and keeps an Outperform rating on the shares. The firm adjusted estimates and price targets for several…